Evidence map›Paper›PMID 18088090›Full record

ArticleJournal of medicinal chemistry2008

Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 receptor.

Alexander V Mayorov, Minying Cai, Erin S Palmer, Matthew M Dedek, James P Cain, April R Van Scoy, Bahar Tan, Josef Vagner, Dev Trivedi, Victor J Hruby

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Demonstration of a Common DPheJournal of medicinal chemistry · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alexander V MayorovDepartment of Chemistry, University of Arizona, Tucson, Arizona 85721, USA.
Minying Cai
Erin S Palmer
Matthew M Dedek
James P Cain
April R Van Scoy
Bahar Tan
Josef Vagner
Dev Trivedi
Victor J Hruby
University of Arizona · US

Funding

THERAPEUTIC PROFILES OF OPIOID DELTA RECEPTORS--NEW MODALITIESP01DA006284 · NIDA · UNIVERSITY OF ARIZONA · PI HRUBY, VICTOR J · 1989 to 2015
$14.8M
PEPTIDE HORMONE STRUCTURE &FUNCTIONR01DK017420 · NIDDK · UNIVERSITY OF ARIZONA · PI HRUBY, VICTOR J · 1986 to 2010
$2.8M
NIDA NIH HHS DA-06284NIDA NIH HHS P01 DA006284NIDDK NIH HHS DK-17420NIDDK NIH HHS R01 DK017420
6 · The paper itself

Abstract

A variety of dicarboxylic acid linkers introduced between the alpha-amino group of Pro(6) and the -amino group of Lys(10) of the cyclic lactam alpha-melanocyte-stimulating hormone (alpha-MSH)-derived Pro(6)-D-Phe(7)/D-Nal(2')(7)-Arg(8)-Trp(9)-Lys(10)-NH2 pentapeptide template lead to nanomolar range and selective hMC3R agonists and antagonists. Replacement of the Pro(6) residue and the dicarboxylic acid linker with 2,3-pyrazine-dicarboxylic acid furnished a highly selective nanomolar range hMC3R partial agonist (analogue 12, c[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2, EC50 = 27 nM, 70% max cAMP) and an hMC3R antagonist (analogue 13, c[CO-2,3-pyrazine-CO-D-Nal(2')-Arg-Trp-Lys]-NH2, IC50 = 23 nM). Modeling experiments suggest that 2,3-pyrazinedicarboxylic acid stabilizes a beta-turn-like structure with the D-Phe/D-Nal(2') residues, which explains the high potency of the corresponding peptides. Placement of a Nle residue in position 6 produced a hMC3R/hMC5R antagonist (analogue 15, c[CO-(CH 2)2-CO-Nle-D-Nal(2')-Arg-Trp-Lys]-NH2, IC50 = 12 and 17 nM, respectively), similarly to the previously described cyclic gamma-melanocyte-stimulating hormone (gamma-MSH)-derived hMC3R/hMC5R antagonists. These newly developed melanotropins will serve as critical biochemical tools for elucidating the full spectrum of functions performed by the physiologically important melanocortin-3 receptor.

Indexed as

alpha-MSHBinding, CompetitiveCell LineCyclic AMPHumansLactamsModels, MolecularPeptides, CyclicRadioligand AssayReceptor, Melanocortin, Type 3Structure-Activity Relationshipalpha-MSHCyclic AMPLactamsMC3R protein, humanPeptides, CyclicReceptor, Melanocortin, Type 3

Identifiers

PMID18088090
PMCPMC2587288
OpenAlexW2038882708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.